Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vilobelimab + best supportive care
- Development stage
- Unknown
- Lead developer
- InflaRx
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Vilobelimab + best supportive care is a combination regimen for severe COVID-19, specifically indicated for patients requiring invasive mechanical ventilation or extracorporeal membrane oxygenation. **Vilobelimab** is a chimeric monoclonal immunoglobulin G4 antibody that binds selectively with high affinity to soluble human complement component C5a, blocking its downstream inflammatory effects. This agent is administered in addition to best supportive care (SOC), which includes all standard therapies for critical COVID-19 as per clinical guidelines. The combination has demonstrated a statistically significant survival benefit and reduced need for renal replacement therapy in randomized controlled trials. Vilobelimab (marketed as Gohibic) was developed by InflaRx and has received emergency/conditional approval for the treatment of severe COVID-19 in select regions.
- Brand names
- vilobelimab
- Other names
- vilobelimab plus standard of carevilobelimab + SOCvilobelimab plus best supportive care
02
Targets
Complement component C5a
Beyond the preview
Go deeper on vilobelimab + best supportive care.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vilobelimab + best supportive care.